1Hypertension Detection and Follow-up Programe Cooperative Group. Five-year findings of the hypertension detection and follow-up programe.Ⅱ. Mortality by race-sex and age. JAMA, 1979, 242: 2572-2577.
2MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog in Cardiovasc Dis, 1986,29: 99-181.
3Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003,289: 2560-2572.
4Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Am J Hypertens, 1995, 8: 189-192.
5Beard K, Bulpitt C, Mascie-Taylor H, et al. Management of elderly patients with sustained hypertension.Br Med J, 1992, 304: 412-416.
6Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I- converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest, 1990, 86: 1343-1346.
7Stavaroulakis GA, Makris TK, Kreisp PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-enzyme gene polymorphism.Cardiovasc Drugs Ther, 2000, 14: 427-432.
8Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension, 2003, 41: 398-403.
9Hiraga H, Oshima T, Watanabe M, et al. Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension, 1996, 27: 569-572.
